ONTOLOGY REPORT - ANNOTATIONS
| Term: | scopolamine |
|
| Accession: | CHEBI:16794
|
browse the term
|
| Definition: | A tropane alkaloid that is the (S)-tropic acid ester of 6beta,7beta-epoxy-1alphaH,5alphaH-tropan-3alpha-ol. |
| Synonyms: | exact_synonym: | (1R,2R,4S,5S,7S)-9-methyl-3-oxa-9-azatricyclo[3.3.1.0(2,4)]non-7-yl (2S)-3-hydroxy-2-phenylpropanoate |
| | related_synonym: | (1S,3S,5R,6R,7S)-6,7-epoxytropan-3-yl (2S)-3-hydroxy-2-phenylpropanoate; 6,7-Epoxytropine tropate; 6-beta,7-beta-Epoxy-3-alpha-tropanyl S-(-)-tropate; C17H21NO4; CN1[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)c1ccccc1; Hyoscine; InChI=1S/C17H21NO4/c1-18-13-7-11(8-14(18)16-15(13)22-16)21-17(20)12(9-19)10-5-3-2-4-6-10/h2-6,11-16,19H,7-9H2,1H3/t11-,12-,13-,14+,15-,16+/m1/s1; InChIKey=STECJAGHUSJQJN-FWXGHANASA-N; Transderm-Scop; alpha-(Hydroxymethyl)benzeneacetic acid 9-methyl-3-oxa-9-azatricyclo(3.3.1.0(2.4))non-7-yl ester; scopine (-)-tropate |
| | alt_id: | CHEBI:15066; CHEBI:26610; CHEBI:9056 |
| | xref_casrn: | 51-34-3 |
| | xref: | ChEMBL:679689 "ChEMBL COMPOUND"; DrugBank:DB00747 "DrugBank"; KEGG COMPOUND:51-34-3 "CAS Registry Number"; KEGG COMPOUND:C01851 "KEGG COMPOUND"; KEGG DRUG:D00138 "KEGG DRUG" |
| | xref_mesh: | MESH:D012601 |
| | cyclic_relationship: | is_conjugate_base_of CHEBI:61269 |
|
|
scopolamine
|
| G |
Abcb1a |
ATP-binding cassette, sub-family B (MDR/TAP), member 1A |
|
decreases expression |
EXP |
4 |
21,709,855 |
21,796,628 |
RGD:6480464 |
CTD |
| G |
Abcg1 |
ATP-binding cassette, subfamily G (WHITE), member 1 |
|
increases expression |
EXP |
20 |
9,390,485 |
9,459,574 |
RGD:6480464 |
CTD |
| G |
Ache |
acetylcholinesterase |
|
multiple interactions |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Ache |
acetylcholinesterase |
|
increases activity |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Ache |
acetylcholinesterase |
|
affects response to substance |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Ache |
acetylcholinesterase |
|
increases activity |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Ache |
acetylcholinesterase |
|
multiple interactions |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Ache |
acetylcholinesterase |
|
multiple interactions |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Ache |
acetylcholinesterase |
|
multiple interactions |
EXP |
|
|
|
RGD:6480464 |
CTD |
| G |
Ache |
acetylcholinesterase |
|
decreases activity |
EXP |
|
|
|
RGD:6480464 |
CTD |
| G |
Ache |
acetylcholinesterase |
|
multiple interactions |
EXP |
|
|
|
RGD:6480464 |
CTD |
| G |
Ache |
acetylcholinesterase |
|
increases activity |
EXP |
|
|
|
RGD:6480464 |
CTD |
| G |
Ache |
acetylcholinesterase |
|
increases activity |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Ache |
acetylcholinesterase |
|
increases response to substance |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Adora3 |
adenosine A3 receptor |
|
multiple interactions |
ISO |
2 |
201,157,782 |
201,161,425 |
RGD:6480464 |
CTD |
| G |
Agt |
angiotensinogen (serpin peptidase inhibitor, clade A, member 8) |
|
multiple interactions |
ISO |
19 |
54,738,556 |
54,750,349 |
RGD:6480464 |
CTD |
| G |
Aplp2 |
amyloid beta (A4) precursor-like protein 2 |
|
increases expression |
EXP |
|
|
|
RGD:6480464 |
CTD |
| G |
App |
amyloid beta (A4) precursor protein |
|
decreases cleavage |
ISO |
11 |
24,457,855 |
24,693,851 |
RGD:6480464 |
CTD |
| G |
Arc |
activity-regulated cytoskeleton-associated protein |
|
decreases expression |
EXP |
7 |
112,771,937 |
112,775,381 |
RGD:6480464 |
CTD |
| G |
Arg2 |
arginase type II |
|
decreases expression |
EXP |
6 |
101,901,653 |
101,928,282 |
RGD:6480464 |
CTD |
| G |
Arl4d |
ADP-ribosylation factor-like 4D |
|
decreases expression |
EXP |
10 |
90,700,469 |
90,702,625 |
RGD:6480464 |
CTD |
| G |
Avp |
arginine vasopressin |
|
multiple interactions |
EXP |
3 |
118,205,007 |
118,206,985 |
RGD:6480464 |
CTD |
| G |
Avpr1a |
arginine vasopressin receptor 1A |
|
multiple interactions |
EXP |
7 |
62,225,537 |
62,229,461 |
RGD:6480464 |
CTD |
| G |
Bax |
Bcl2-associated X protein |
|
increases expression |
ISO |
1 |
95,933,023 |
95,938,176 |
RGD:6480464 |
CTD |
| G |
Bcat1 |
branched chain amino acid transaminase 1, cytosolic |
|
increases expression |
EXP |
4 |
182,641,517 |
182,692,917 |
RGD:6480464 |
CTD |
| G |
Bcl2 |
B-cell CLL/lymphoma 2 |
|
decreases expression |
ISO |
13 |
12,730,736 |
12,905,108 |
RGD:6480464 |
CTD |
| G |
Bdnf |
brain-derived neurotrophic factor |
|
multiple interactions |
EXP |
|
|
|
RGD:6480464 |
CTD |
| G |
Bdnf |
brain-derived neurotrophic factor |
|
multiple interactions |
EXP |
|
|
|
RGD:6480464 |
CTD |
| G |
Cacna1d |
calcium channel, voltage-dependent, L type, alpha 1D subunit |
|
increases expression |
EXP |
16 |
5,383,259 |
5,703,361 |
RGD:6480464 |
CTD |
| G |
Camkk2 |
calcium/calmodulin-dependent protein kinase kinase 2, beta |
|
decreases expression |
EXP |
12 |
34,907,317 |
34,938,479 |
RGD:6480464 |
CTD |
| G |
Cartpt |
CART prepropeptide |
|
decreases expression |
EXP |
2 |
30,889,817 |
30,891,837 |
RGD:6480464 |
CTD |
| G |
Casp3 |
caspase 3 |
|
increases expression |
ISO |
16 |
48,944,226 |
48,962,420 |
RGD:6480464 |
CTD |
| G |
Cat |
catalase |
|
multiple interactions |
ISO |
3 |
88,654,077 |
88,686,212 |
RGD:6480464 |
CTD |
| G |
Cat |
catalase |
|
decreases activity |
ISO |
3 |
88,654,077 |
88,686,212 |
RGD:6480464 |
CTD |
| G |
Cd3e |
CD3 molecule, epsilon |
|
decreases expression |
EXP |
8 |
47,947,257 |
47,958,419 |
RGD:6480464 |
CTD |
| G |
Chat |
choline O-acetyltransferase |
|
decreases activity |
ISO |
16 |
7,913,026 |
7,965,985 |
RGD:6480464 |
CTD |
| G |
Chat |
choline O-acetyltransferase |
|
multiple interactions |
ISO |
16 |
7,913,026 |
7,965,985 |
RGD:6480464 |
CTD |
| G |
Chrm1 |
cholinergic receptor, muscarinic 1 |
|
multiple interactions |
EXP |
1 |
211,351,738 |
211,353,120 |
RGD:6480464 |
CTD |
| G |
Chrm4 |
cholinergic receptor, muscarinic 4 |
|
increases response to substance |
ISO |
3 |
76,301,988 |
76,309,729 |
RGD:6480464 |
CTD |
| G |
Chrm5 |
cholinergic receptor, muscarinic 5 |
|
decreases response to substance |
ISO |
3 |
98,326,809 |
98,378,531 |
RGD:6480464 |
CTD |
| G |
Chrna4 |
cholinergic receptor, nicotinic, alpha 4 (neuronal) |
|
affects binding |
ISO |
3 |
170,171,214 |
170,185,998 |
RGD:6480464 |
CTD |
| G |
Chrna4 |
cholinergic receptor, nicotinic, alpha 4 (neuronal) |
|
multiple interactions |
ISO |
3 |
170,171,214 |
170,185,998 |
RGD:6480464 |
CTD |
| G |
Chrnb2 |
cholinergic receptor, nicotinic, beta 2 (neuronal) |
|
affects binding |
ISO |
2 |
181,961,373 |
181,969,581 |
RGD:6480464 |
CTD |
| G |
Chrnb2 |
cholinergic receptor, nicotinic, beta 2 (neuronal) |
|
multiple interactions |
ISO |
2 |
181,961,373 |
181,969,581 |
RGD:6480464 |
CTD |
| G |
Coch |
coagulation factor C homolog, cochlin (Limulus polyphemus) |
|
decreases expression |
EXP |
6 |
71,692,946 |
71,697,056 |
RGD:6480464 |
CTD |
| G |
Coro1b |
coronin, actin-binding protein, 1B |
|
increases expression |
EXP |
1 |
206,733,360 |
206,738,018 |
RGD:6480464 |
CTD |
| G |
Cox5b |
cytochrome c oxidase subunit Vb |
|
increases expression |
EXP |
9 |
35,625,478 |
35,627,304 |
RGD:6480464 |
CTD |
| G |
Cryab |
crystallin, alpha B |
|
increases expression |
EXP |
8 |
54,107,824 |
54,111,502 |
RGD:6480464 |
CTD |
| G |
Csf2 |
colony stimulating factor 2 (granulocyte-macrophage) |
|
multiple interactions |
ISO |
10 |
39,665,850 |
39,667,831 |
RGD:6480464 |
CTD |
| G |
Csf2 |
colony stimulating factor 2 (granulocyte-macrophage) |
|
decreases response to substance |
ISO |
10 |
39,665,850 |
39,667,831 |
RGD:6480464 |
CTD |
| G |
Cxcr5 |
chemokine (C-X-C motif) receptor 5 |
|
decreases expression |
EXP |
8 |
47,485,125 |
47,498,509 |
RGD:6480464 |
CTD |
| G |
Ddc |
dopa decarboxylase (aromatic L-amino acid decarboxylase) |
|
decreases expression |
EXP |
14 |
92,698,636 |
92,788,635 |
RGD:6480464 |
CTD |
| G |
Dguok |
deoxyguanosine kinase |
|
increases expression |
EXP |
4 |
117,697,251 |
117,725,383 |
RGD:6480464 |
CTD |
| G |
Dio2 |
deiodinase, iodothyronine, type II |
|
increases expression |
EXP |
6 |
114,307,758 |
114,317,563 |
RGD:6480464 |
CTD |
| G |
Dusp5 |
dual specificity phosphatase 5 |
|
decreases expression |
EXP |
1 |
259,754,234 |
259,767,645 |
RGD:6480464 |
CTD |
| G |
Dusp6 |
dual specificity phosphatase 6 |
|
decreases expression |
EXP |
7 |
36,893,264 |
36,897,494 |
RGD:6480464 |
CTD |
| G |
Egfr |
epidermal growth factor receptor |
|
decreases expression |
EXP |
14 |
97,617,358 |
97,788,211 |
RGD:6480464 |
CTD |
| G |
Egr1 |
early growth response 1 |
|
decreases expression |
EXP |
18 |
27,343,919 |
27,346,117 |
RGD:6480464 |
CTD |
| G |
Egr1 |
early growth response 1 |
|
multiple interactions |
EXP |
18 |
27,343,919 |
27,346,117 |
RGD:6480464 |
CTD |
| G |
Egr1 |
early growth response 1 |
|
decreases expression |
EXP |
18 |
27,343,919 |
27,346,117 |
RGD:6480464 |
CTD |
| G |
Egr1 |
early growth response 1 |
|
decreases expression |
EXP |
18 |
27,343,919 |
27,346,117 |
RGD:6480464 |
CTD |
| G |
Egr2 |
early growth response 2 |
|
decreases expression |
EXP |
20 |
21,883,885 |
21,888,177 |
RGD:6480464 |
CTD |
| G |
Eif2s1 |
eukaryotic translation initiation factor 2, subunit 1 alpha |
|
increases expression |
EXP |
6 |
101,495,444 |
101,520,113 |
RGD:6480464 |
CTD |
| G |
Eml1 |
echinoderm microtubule associated protein like 1 |
|
decreases expression |
EXP |
6 |
132,825,590 |
132,880,169 |
RGD:6480464 |
CTD |
| G |
Fos |
FBJ osteosarcoma oncogene |
|
decreases expression |
EXP |
6 |
109,559,135 |
109,562,001 |
RGD:6480464 |
CTD |
| G |
Fos |
FBJ osteosarcoma oncogene |
|
multiple interactions |
EXP |
6 |
109,559,135 |
109,562,001 |
RGD:6480464 |
CTD |
| G |
Fos |
FBJ osteosarcoma oncogene |
|
multiple interactions |
EXP |
6 |
109,559,135 |
109,562,001 |
RGD:6480464 |
CTD |
| G |
Fos |
FBJ osteosarcoma oncogene |
|
multiple interactions |
EXP |
6 |
109,559,135 |
109,562,001 |
RGD:6480464 |
CTD |
| G |
Fos |
FBJ osteosarcoma oncogene |
|
increases expression |
EXP |
6 |
109,559,135 |
109,562,001 |
RGD:6480464 |
CTD |
| G |
Fos |
FBJ osteosarcoma oncogene |
|
multiple interactions |
EXP |
6 |
109,559,135 |
109,562,001 |
RGD:6480464 |
CTD |
| G |
Fos |
FBJ osteosarcoma oncogene |
|
decreases expression |
EXP |
6 |
109,559,135 |
109,562,001 |
RGD:6480464 |
CTD |
| G |
Fos |
FBJ osteosarcoma oncogene |
|
increases expression |
EXP |
6 |
109,559,135 |
109,562,001 |
RGD:6480464 |
CTD |
| G |
Fos |
FBJ osteosarcoma oncogene |
|
increases expression |
EXP |
6 |
109,559,135 |
109,562,001 |
RGD:6480464 |
CTD |
| G |
Fos |
FBJ osteosarcoma oncogene |
|
decreases expression |
EXP |
6 |
109,559,135 |
109,562,001 |
RGD:6480464 |
CTD |
| G |
Gabbr1 |
gamma-aminobutyric acid (GABA) B receptor 1 |
|
increases expression |
EXP |
20 |
1,553,297 |
1,582,426 |
RGD:6480464 |
CTD |
| G |
Gjb2 |
gap junction protein, beta 2 |
|
increases expression |
EXP |
15 |
36,153,526 |
36,159,490 |
RGD:6480464 |
CTD |
| G |
Gpc3 |
glypican 3 |
|
decreases expression |
EXP |
X |
139,192,115 |
139,560,649 |
RGD:6480464 |
CTD |
| G |
Gypc |
glycophorin C (Gerbich blood group) |
|
decreases expression |
EXP |
18 |
24,974,608 |
25,006,999 |
RGD:6480464 |
CTD |
| G |
Homer1 |
homer homolog 1 (Drosophila) |
|
decreases expression |
EXP |
|
|
|
RGD:6480464 |
CTD |
| G |
Hrh1 |
histamine receptor H 1 |
|
multiple interactions |
EXP |
4 |
150,431,239 |
150,432,699 |
RGD:6480464 |
CTD |
| G |
Hrh2 |
histamine receptor H 2 |
|
multiple interactions |
EXP |
17 |
16,497,967 |
16,499,043 |
RGD:6480464 |
CTD |
| G |
Hrh2 |
histamine receptor H 2 |
|
multiple interactions |
EXP |
17 |
16,497,967 |
16,499,043 |
RGD:6480464 |
CTD |
| G |
Hrh3 |
histamine receptor H3 |
|
multiple interactions |
EXP |
3 |
169,154,980 |
169,160,064 |
RGD:6480464 |
CTD |
| G |
Hspa2 |
heat shock protein 2 |
|
increases expression |
EXP |
6 |
99,000,541 |
99,003,041 |
RGD:6480464 |
CTD |
| G |
Htr1a |
5-hydroxytryptamine (serotonin) receptor 1A, G protein-coupled |
|
multiple interactions |
EXP |
2 |
36,434,518 |
36,435,786 |
RGD:6480464 |
CTD |
| G |
Htr2c |
5-hydroxytryptamine (serotonin) receptor 2C, G protein-coupled |
|
increases expression |
EXP |
X |
31,012,921 |
31,244,127 |
RGD:6480464 |
CTD |
| G |
Htr6 |
5-hydroxytryptamine (serotonin) receptor 6, G protein-coupled |
|
decreases expression |
EXP |
|
|
|
RGD:6480464 |
CTD |
| G |
Ifng |
interferon gamma |
|
multiple interactions |
EXP |
7 |
57,621,756 |
57,625,792 |
RGD:6480464 |
CTD |
| G |
Ifng |
interferon gamma |
|
increases expression |
EXP |
7 |
57,621,756 |
57,625,792 |
RGD:6480464 |
CTD |
| G |
Il1a |
interleukin 1 alpha |
|
decreases response to substance |
ISO |
3 |
116,913,612 |
116,924,114 |
RGD:6480464 |
CTD |
| G |
Il1b |
interleukin 1 beta |
|
increases expression |
ISO |
3 |
116,964,422 |
116,970,867 |
RGD:6480464 |
CTD |
| G |
Il1b |
interleukin 1 beta |
|
multiple interactions |
ISO |
3 |
116,964,422 |
116,970,867 |
RGD:6480464 |
CTD |
| G |
Il1b |
interleukin 1 beta |
|
increases expression |
ISO |
3 |
116,964,422 |
116,970,867 |
RGD:6480464 |
CTD |
| G |
Il1b |
interleukin 1 beta |
|
increases expression |
EXP |
3 |
116,964,422 |
116,970,867 |
RGD:6480464 |
CTD |
| G |
Il1b |
interleukin 1 beta |
|
multiple interactions |
EXP |
3 |
116,964,422 |
116,970,867 |
RGD:6480464 |
CTD |
| G |
Il1rn |
interleukin 1 receptor antagonist |
|
multiple interactions |
ISO |
3 |
2,607,800 |
2,613,216 |
RGD:6480464 |
CTD |
| G |
Il6 |
interleukin 6 |
|
multiple interactions |
EXP |
4 |
456,799 |
461,376 |
RGD:6480464 |
CTD |
| G |
Il6 |
interleukin 6 |
|
increases expression |
ISO |
4 |
456,799 |
461,376 |
RGD:6480464 |
CTD |
| G |
Il6 |
interleukin 6 |
|
increases expression |
EXP |
4 |
456,799 |
461,376 |
RGD:6480464 |
CTD |
| G |
Itpr1 |
inositol 1,4,5-trisphosphate receptor, type 1 |
|
increases expression |
EXP |
4 |
143,705,360 |
144,030,051 |
RGD:6480464 |
CTD |
| G |
Jun |
jun proto-oncogene |
|
multiple interactions |
EXP |
5 |
115,358,166 |
115,361,259 |
RGD:6480464 |
CTD |
| G |
Junb |
jun B proto-oncogene |
|
decreases expression |
EXP |
19 |
24,831,536 |
24,833,320 |
RGD:6480464 |
CTD |
| G |
Kcna4 |
potassium voltage-gated channel, shaker-related subfamily, member 4 |
|
increases expression |
EXP |
3 |
92,781,795 |
92,784,921 |
RGD:6480464 |
CTD |
| G |
Kcnb1 |
potassium voltage gated channel, Shab-related subfamily, member 1 |
|
increases expression |
EXP |
3 |
158,250,001 |
158,345,927 |
RGD:6480464 |
CTD |
| G |
Kcnb1 |
potassium voltage gated channel, Shab-related subfamily, member 1 |
|
increases expression |
EXP |
3 |
158,250,001 |
158,345,927 |
RGD:6480464 |
CTD |
| G |
Kcnd2 |
potassium voltage-gated channel, Shal-related subfamily, member 2 |
|
decreases expression |
EXP |
4 |
47,541,787 |
48,047,924 |
RGD:6480464 |
CTD |
| G |
Klf2 |
Kruppel-like factor 2 (lung) |
|
decreases expression |
EXP |
16 |
17,941,780 |
17,943,730 |
RGD:6480464 |
CTD |
| G |
Klf4 |
Kruppel-like factor 4 (gut) |
|
decreases expression |
EXP |
5 |
73,446,928 |
73,451,286 |
RGD:6480464 |
CTD |
| G |
Lnpep |
leucyl/cystinyl aminopeptidase |
|
multiple interactions |
ISO |
1 |
56,063,361 |
56,151,257 |
RGD:6480464 |
CTD |
| G |
Madd |
MAP-kinase activating death domain |
|
increases expression |
EXP |
3 |
75,498,321 |
75,541,073 |
RGD:6480464 |
CTD |
| G |
Mapt |
microtubule-associated protein tau |
|
decreases expression |
EXP |
10 |
93,411,098 |
93,508,762 |
RGD:6480464 |
CTD |
| G |
Muc5ac |
mucin 5AC, oligomeric mucus/gel-forming |
|
decreases expression |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Muc5ac |
mucin 5AC, oligomeric mucus/gel-forming |
|
decreases expression |
EXP |
|
|
|
RGD:6480464 |
CTD |
| G |
Ngf |
nerve growth factor (beta polypeptide) |
|
decreases response to substance |
EXP |
2 |
197,621,726 |
197,632,960 |
RGD:6480464 |
CTD |
| G |
Ngf |
nerve growth factor (beta polypeptide) |
|
increases response to substance |
ISO |
2 |
197,621,726 |
197,632,960 |
RGD:6480464 |
CTD |
| G |
Ngf |
nerve growth factor (beta polypeptide) |
|
multiple interactions |
EXP |
2 |
197,621,726 |
197,632,960 |
RGD:6480464 |
CTD |
| G |
Nova1 |
neuro-oncological ventral antigen 1 |
|
multiple interactions |
EXP |
6 |
66,193,472 |
66,320,240 |
RGD:6480464 |
CTD |
| G |
Nova2 |
neuro-oncological ventral antigen 2 |
|
multiple interactions |
EXP |
1 |
78,258,933 |
78,310,851 |
RGD:6480464 |
CTD |
| G |
Nqo2 |
NAD(P)H dehydrogenase, quinone 2 |
|
increases expression |
EXP |
17 |
37,255,630 |
37,283,753 |
RGD:6480464 |
CTD |
| G |
Nr1d1 |
nuclear receptor subfamily 1, group D, member 1 |
|
decreases expression |
EXP |
10 |
87,541,246 |
87,548,186 |
RGD:6480464 |
CTD |
| G |
Nr4a1 |
nuclear receptor subfamily 4, group A, member 1 |
|
decreases expression |
EXP |
7 |
140,012,807 |
140,020,590 |
RGD:6480464 |
CTD |
| G |
Ntf3 |
neurotrophin 3 |
|
multiple interactions |
EXP |
4 |
162,435,781 |
162,506,961 |
RGD:6480464 |
CTD |
| G |
Ntrk2 |
neurotrophic tyrosine kinase, receptor, type 2 |
|
multiple interactions |
EXP |
17 |
11,494,463 |
11,811,654 |
RGD:6480464 |
CTD |
| G |
Ntrk3 |
neurotrophic tyrosine kinase, receptor, type 3 |
|
multiple interactions |
EXP |
1 |
133,925,530 |
134,302,139 |
RGD:6480464 |
CTD |
| G |
Pdcd4 |
programmed cell death 4 |
|
increases expression |
EXP |
1 |
260,183,648 |
260,202,032 |
RGD:6480464 |
CTD |
| G |
Pdyn |
prodynorphin |
|
decreases response to substance |
ISO |
3 |
117,291,025 |
117,303,367 |
RGD:6480464 |
CTD |
| G |
Pdyn |
prodynorphin |
|
increases expression |
EXP |
3 |
117,291,025 |
117,303,367 |
RGD:6480464 |
CTD |
| G |
Pdyn |
prodynorphin |
|
multiple interactions |
ISO |
3 |
117,291,025 |
117,303,367 |
RGD:6480464 |
CTD |
| G |
Penk |
proenkephalin |
|
multiple interactions |
EXP |
5 |
17,509,323 |
17,514,265 |
RGD:6480464 |
CTD |
| G |
Pgam1 |
phosphoglycerate mutase 1 (brain) |
|
decreases expression |
EXP |
|
|
|
RGD:6480464 |
CTD |
| G |
Prep |
prolyl endopeptidase |
|
increases response to substance |
EXP |
20 |
49,024,917 |
49,144,670 |
RGD:6480464 |
CTD |
| G |
Prep |
prolyl endopeptidase |
|
multiple interactions |
EXP |
20 |
49,024,917 |
49,144,670 |
RGD:6480464 |
CTD |
| G |
Prep |
prolyl endopeptidase |
|
increases expression |
EXP |
20 |
49,024,917 |
49,144,670 |
RGD:6480464 |
CTD |
| G |
Prkra |
protein kinase, interferon inducible double stranded RNA dependent activator |
|
decreases expression |
EXP |
3 |
59,327,653 |
59,346,511 |
RGD:6480464 |
CTD |
| G |
Psen2 |
presenilin 2 |
|
decreases expression |
EXP |
13 |
95,934,674 |
95,951,836 |
RGD:6480464 |
CTD |
| G |
Rab14 |
RAB14, member RAS oncogene family |
|
increases expression |
EXP |
3 |
14,245,693 |
14,255,984 |
RGD:6480464 |
CTD |
| G |
Rapgef3 |
Rap guanine nucleotide exchange factor (GEF) 3 |
|
decreases expression |
EXP |
7 |
136,452,945 |
136,474,659 |
RGD:6480464 |
CTD |
| G |
Rela |
v-rel reticuloendotheliosis viral oncogene homolog A (avian) |
|
multiple interactions |
ISO |
1 |
208,262,669 |
208,273,148 |
RGD:6480464 |
CTD |
| G |
Rela |
v-rel reticuloendotheliosis viral oncogene homolog A (avian) |
|
multiple interactions |
ISO |
1 |
208,262,669 |
208,273,148 |
RGD:6480464 |
CTD |
| G |
Rela |
v-rel reticuloendotheliosis viral oncogene homolog A (avian) |
|
multiple interactions |
ISO |
1 |
208,262,669 |
208,273,148 |
RGD:6480464 |
CTD |
| G |
Rela |
v-rel reticuloendotheliosis viral oncogene homolog A (avian) |
|
multiple interactions |
ISO |
1 |
208,262,669 |
208,273,148 |
RGD:6480464 |
CTD |
| G |
Rem2 |
RAS (RAD and GEM) like GTP binding 2 |
|
decreases expression |
EXP |
15 |
32,539,996 |
32,544,475 |
RGD:6480464 |
CTD |
| G |
RGD1565996 |
similar to DnaJ homolog subfamily B member 6 (Heat shock protein J2) |
|
increases expression |
EXP |
11 |
52,756,698 |
52,757,185 |
RGD:6480464 |
CTD |
| G |
Rgs7bp |
regulator of G-protein signaling 7 binding protein |
|
decreases expression |
EXP |
2 |
35,993,050 |
36,085,686 |
RGD:6480464 |
CTD |
| G |
Robo3 |
roundabout, axon guidance receptor, homolog 3 (Drosophila) |
|
decreases expression |
EXP |
8 |
38,668,913 |
38,683,439 |
RGD:6480464 |
CTD |
| G |
Rraga |
Ras-related GTP binding A |
|
increases expression |
EXP |
5 |
105,659,659 |
105,661,254 |
RGD:6480464 |
CTD |
| G |
S100a4 |
S100 calcium-binding protein A4 |
|
decreases expression |
EXP |
2 |
182,885,070 |
182,887,380 |
RGD:6480464 |
CTD |
| G |
S1pr1 |
sphingosine-1-phosphate receptor 1 |
|
increases expression |
EXP |
2 |
211,851,304 |
211,855,511 |
RGD:6480464 |
CTD |
| G |
Scamp2 |
secretory carrier membrane protein 2 |
|
increases expression |
EXP |
8 |
61,316,260 |
61,342,886 |
RGD:6480464 |
CTD |
| G |
Sigmar1 |
sigma non-opioid intracellular receptor 1 |
|
multiple interactions |
ISO |
5 |
59,162,537 |
59,165,315 |
RGD:6480464 |
CTD |
| G |
Sult1a1 |
sulfotransferase family, cytosolic, 1A, phenol-preferring, member 1 |
|
increases expression |
EXP |
1 |
185,829,205 |
185,832,725 |
RGD:6480464 |
CTD |
| G |
Syp |
synaptophysin |
|
multiple interactions |
EXP |
X |
26,890,307 |
26,905,319 |
RGD:6480464 |
CTD |
| G |
Syp |
synaptophysin |
|
increases expression |
EXP |
X |
26,890,307 |
26,905,319 |
RGD:6480464 |
CTD |
| G |
Tac1 |
tachykinin, precursor 1 |
|
decreases response to substance |
EXP |
4 |
32,649,666 |
32,657,632 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
multiple interactions |
ISO |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
increases expression |
ISO |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
increases expression |
ISO |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
multiple interactions |
ISO |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
increases expression |
EXP |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
increases expression |
ISO |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tnrc6a |
trinucleotide repeat containing 6a |
|
decreases expression |
EXP |
1 |
181,982,994 |
182,053,510 |
RGD:6480464 |
CTD |
| G |
Tpd52l1 |
tumor protein D52-like 1 |
|
increases expression |
EXP |
1 |
26,788,964 |
26,951,930 |
RGD:6480464 |
CTD |
| G |
Vgf |
VGF nerve growth factor inducible |
|
decreases expression |
EXP |
12 |
20,903,304 |
20,906,327 |
RGD:6480464 |
CTD |
| G |
Vip |
vasoactive intestinal peptide |
|
decreases response to substance |
EXP |
1 |
36,361,513 |
36,369,594 |
RGD:6480464 |
CTD |
Term paths to the root
|